Details for Patent: 11,034,660
✉ Email this page to a colleague
Which drugs does patent 11,034,660 protect, and when does it expire?
Patent 11,034,660 protects XPOVIO and is included in one NDA.
This patent has one hundred patent family members in thirty-seven countries.
Summary for Patent: 11,034,660
Title: | Hydrazide containing nuclear transport modulators and uses thereof |
Abstract: | The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. |
Inventor(s): | Sandanayaka; Vincent P. (Northboro, MA), Shacham; Sharon (Newton, MA), McCauley; Dilara (Arlington, MA), Shechter; Sharon (Andover, MA) |
Assignee: | Karyopharm Therapeutics Inc. (Newton, MA) |
Application Number: | 16/696,702 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 11,034,660
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | 11,034,660 | ⤷ Try for Free | XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES | ⤷ Try for Free | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-001 | Jul 3, 2019 | RX | Yes | No | 11,034,660 | ⤷ Try for Free | XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Try for Free | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 11,034,660 | ⤷ Try for Free | XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES | ⤷ Try for Free | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-002 | Apr 15, 2021 | RX | Yes | No | 11,034,660 | ⤷ Try for Free | XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY | ⤷ Try for Free | ||||
Karyopharm Theraps | XPOVIO | selinexor | TABLET;ORAL | 212306-003 | Apr 15, 2021 | RX | Yes | No | 11,034,660 | ⤷ Try for Free | XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,034,660
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 2736887 | ⤷ Try for Free | 301119 | Netherlands | ⤷ Try for Free |
European Patent Office | 2736887 | ⤷ Try for Free | PA2021007 | Lithuania | ⤷ Try for Free |
European Patent Office | 2736887 | ⤷ Try for Free | CA 2021 00031 | Denmark | ⤷ Try for Free |
European Patent Office | 2736887 | ⤷ Try for Free | LUC00219 | Luxembourg | ⤷ Try for Free |
European Patent Office | 2736887 | ⤷ Try for Free | 2021C/532 | Belgium | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |